Wentao Han | Medicine | Best Researcher Award

Posted on by sciencefather

Dr. Wentao Han | Medicine | Best Researcher Award

Dr. Wentao Han, Department of Ophthalmology, The Second Xiangya Hospital, Central South University, China

Wentao Han is a dedicated ophthalmology researcher specializing in diabetic eye complications, dry eye syndrome, and gene therapy. Currently pursuing his research at the Second Xiangya Hospital of Central South University, China, he has demonstrated a strong passion for advancing medical science through innovative studies. His contributions to ocular disease research, particularly in understanding the gut-eye axis and corneal wound healing, highlight his interdisciplinary approach. He has authored multiple high-impact journal articles and actively collaborates with global scholars. His research on machine learning applications in medical diagnosis showcases his forward-thinking vision in integrating AI with healthcare. Beyond academia, Wentao Han serves as a reviewer for prestigious journals, contributing to the integrity of scientific publications. His dedication to translational medicine and biomarker identification continues to shape new therapeutic strategies. His work aims to bridge laboratory findings with clinical applications, improving patient outcomes in ophthalmology and metabolic diseases.

Professional Profile 

Orcid

Suitability for the Research for Best Researcher Award – Wentao Han

Wentao Han demonstrates a strong research background in ophthalmology, particularly in the areas of diabetic eye complications, dry eye syndrome, and corneal wound healing. Currently pursuing research at the Second Xiangya Hospital of Central South University, he has made notable contributions to the field, with multiple high-impact publications in reputable journals. His expertise in the “gut metabolites–inflammation–eye axis” and gene therapy for Meibomian Gland Dysfunction (MGD) highlights his innovative approach to addressing critical challenges in ophthalmology.

His publication record is impressive, with multiple papers in Q1 and Q2 journals, including Pharmaceutics, The Ocular Surface, Acta Diabetologica, and Journal of Medical Internet Research. Notably, his work on machine learning prediction models, autophagy in retinal precursor cells, and the gut-eye axis showcases a multidisciplinary research approach. His role as an invited reviewer for respected journals further establishes his credibility in the academic community.

🎓 Education 

Wentao Han is currently pursuing advanced medical research at Central South University, Changsha, China, within the Department of Ophthalmology at the Second Xiangya Hospital. His academic journey reflects a deep commitment to ophthalmic research, focusing on diabetic retinopathy, ocular surface disorders, and corneal healing mechanisms. Through rigorous training and hands-on experience in clinical settings, he has honed his expertise in evidence-based medicine and translational research. His coursework and mentorship under leading ophthalmologists have allowed him to integrate molecular biology with patient-centered investigations. Additionally, he actively participates in research seminars, workshops, and scientific collaborations, reinforcing his knowledge of bioinformatics, gene therapy, and regenerative medicine. His strong foundation in medical sciences, combined with a keen interest in technological advancements, positions him as a promising young researcher in ophthalmology. His education has equipped him with critical skills to contribute to groundbreaking discoveries in the field of ocular diseases.

💼 Professional Experience 

As a researcher in ophthalmology at the Second Xiangya Hospital of Central South University, Wentao Han has contributed significantly to understanding diabetic eye complications and ocular disease mechanisms. His professional experience includes conducting clinical and preclinical studies on dry eye syndrome, corneal wound healing, and the gut-eye axis. He has extensive expertise in meta-analyses, molecular diagnostics, and the application of artificial intelligence in disease prediction. His work in identifying novel biomarkers for diabetic retinopathy has been widely recognized. Additionally, he collaborates with interdisciplinary teams, integrating bioinformatics and evidence-based medicine to develop innovative treatment approaches. Han’s active involvement in academic publishing and peer review for high-impact journals reflects his commitment to advancing medical knowledge. His current projects involve investigating gene therapy for meibomian gland dysfunction and corneal regeneration, with the aim of translating scientific discoveries into clinical applications that enhance patient care in ophthalmology.

🏅 Awards and Recognition 

Wentao Han has received multiple recognitions for his outstanding contributions to ophthalmic research. He has been an invited reviewer for prestigious journals such as Cell Death Discovery (IF = 7) and Acta Diabetologia (IF = 3.9), underscoring his expertise in diabetes-related ocular disorders. His research on gut metabolites’ role in eye diseases has been acknowledged at international conferences. Several of his published articles in Q1 journals have earned high citations, reflecting their impact on the scientific community. Han has also contributed to the development of machine learning prediction models for gestational diabetes mellitus, further showcasing his interdisciplinary proficiency. His involvement in groundbreaking studies on corneal wound healing has positioned him as a promising young researcher in ophthalmology. With a strong publication record, peer recognition, and contributions to medical advancements, Han continues to be a driving force in translational ophthalmic research and clinical innovation.

🌍 Research Skills On Medicine

Wentao Han possesses a diverse set of research skills that bridge molecular biology, clinical medicine, and artificial intelligence applications in ophthalmology. His expertise includes conducting systematic reviews, meta-analyses, and experimental research on diabetic retinopathy and dry eye syndrome. He is proficient in bioinformatics tools for gene analysis and biomarker identification, which he applies to precision medicine. Han is skilled in laboratory techniques such as immunohistochemistry, cell culture, and animal models for ocular disease studies. His ability to integrate AI and machine learning into medical research has led to innovative predictive models for disease diagnosis. Additionally, his work in gene therapy for corneal and meibomian gland dysfunction highlights his translational research capabilities. Han’s interdisciplinary approach allows him to explore novel therapeutic targets, making significant contributions to evidence-based medicine. His research aims to improve diagnostic accuracy and therapeutic interventions in ophthalmic and metabolic disorders.

đź“– Publication Top Notes

  • Research Progress and Potential Applications of Spermidine in Ocular Diseases
  • Machine Learning Prediction Models for Gestational Diabetes Mellitus: Meta-analysis
    • Authors: Zheqing Zhang, Luqian Yang, Wentao Han, Yaoyu Wu, Linhui Zhang, Chun Gao, Kui Jiang, Yun Liu, Huiqun Wu
    • Citation: Journal of Medical Internet Research, 2022-03-16
    • Year: 2022
    • DOI: 10.2196/26634
  • Genome Analysis and Identification of Key Pathway in Visceral Adipose Tissue from Obesity-Related Diabetes
    • Authors: Wentao Han
    • Citation: Proceedings of the 2021 International Conference on Bioinformatics and Intelligent Computing, 2021-01-22
    • Year: 2021
    • DOI: 10.1145/3448748.3448757
  • Machine Learning Prediction Models for Gestational Diabetes Mellitus: Meta-analysis (Preprint)
    • Authors: Zheqing Zhang, Luqian Yang, Wentao Han, Yaoyu Wu, Linhui Zhang, Chun Gao, Kui Jiang, Yun Liu, Huiqun Wu
    • Citation: Preprint, 2020-12-19
    • Year: 2020
    • DOI: 10.2196/preprints.26634
  • Construction of a Knowledge Graph for Diabetes Complications from Expert-Reviewed Clinical Evidences
    • Authors: Wentao Han
    • Citation: Computer Assisted Surgery (Abingdon, England), 2020-11-25
    • Year: 2020
    • DOI: 10.1080/24699322.2020.1850866
    • PMID: 33275462
  • Association Between Retinol Binding Protein 4 and Diabetic Retinopathy Among Type 2 Diabetic Patients: A Meta-analysis
    • Authors: Wentao Han, Huagen Wei, Weizheng Kong, Jing Wang, Luqian Yang, Huiqun Wu
    • Citation: Acta Diabetologica, 2020-10
    • Year: 2020
    • DOI: 10.1007/s00592-020-01535-3

 

Do Young Kim | Medicine | Best Researcher Award

Posted on by sciencefather

Prof. Do Young Kim | Medicine | Best Researcher Award

Prof. Do Young Kim, Yonsei University College of Medicine South Korea

Do Young Kim is a Professor of Internal Medicine at Yonsei University College of Medicine and a hepatologist at Severance Hospital in Seoul, Korea. Having been part of the faculty since 2007, Dr. Kim is widely recognized for his contributions to hepatology, particularly in hepatocellular carcinoma (HCC). He earned his medical degree from Yonsei University in 1996 and completed his training at Severance Hospital. Dr. Kim’s research experience includes a position as a research associate at Fred Hutchinson Cancer Research Center from 2011 to 2012, where he focused on proteomics and microRNA in HCC.

Professional Profile 

Scopus 

Orcid

Google Scholar

Summary of Suitability for the “Research for Best Researcher Award”

Professor Do Young Kim, a prominent figure in hepatology and internal medicine, has made significant contributions to the field of hepatocellular carcinoma (HCC) and hepatitis C research. As a professor at Yonsei University College of Medicine and a hepatologist at Severance Hospital, he has established himself as a leading expert in his field since 2007. His academic background, including his degree from Yonsei University and specialized training at Severance Hospital, laid a solid foundation for his remarkable career.

His research focus on proteomics and microRNA in HCC, particularly during his tenure at the Fred Hutchinson Cancer Research Center, has led to innovative insights into the mechanisms underlying liver cancer and hepatitis C. This focus has translated into a series of impactful publications, where he has served as the corresponding author in studies that explore new treatment paradigms and diagnostic advancements for HCC. His work on the efficacy and safety of various treatments, including sorafenib and lenvatinib, has become essential reading for clinicians and researchers alike.

🎓 Education 

Dr. Do Young Kim obtained his medical degree from Yonsei University in Seoul, Korea, in 1996. After completing his studies, he underwent medical training at Severance Hospital, where he continued his professional development until 2001. In 2011, Dr. Kim broadened his academic horizons by becoming a research associate at Fred Hutchinson Cancer Research Center, where he focused on proteomics and microRNA in hepatocellular carcinoma (HCC). This international research experience allowed him to deepen his expertise in the molecular aspects of liver cancer. Dr. Kim’s ongoing contributions to medical education and his research have been deeply influenced by his foundational education and global training experiences.

💼 Professional Experience 

Dr. Do Young Kim is currently serving as a Professor of Internal Medicine at Yonsei University College of Medicine and a hepatologist at Severance Hospital in Seoul, Korea. Since joining Severance Hospital in 2007, he has become an integral part of the team, specializing in hepatology and liver diseases. His research has advanced understanding in areas such as hepatocellular carcinoma (HCC) and hepatitis C. In 2011-2012, Dr. Kim expanded his professional expertise by working as a research associate at the Fred Hutchinson Cancer Research Center in Seattle, USA. There, he conducted cutting-edge research in proteomics and microRNA in relation to HCC, which added a new dimension to his medical and scientific career. His ongoing clinical and research contributions have made him a leader in the field of hepatology.

🏅 Awards and Recognition

Dr. Do Young Kim has received significant recognition in the field of hepatology, with several prestigious awards throughout his career. His research on hepatocellular carcinoma (HCC) and hepatitis C has earned him acknowledgment both nationally and internationally. He is particularly recognized for his contributions to clinical practices surrounding HCC and his extensive publication record in highly respected medical journals. His role as a corresponding author in key studies, such as those published in Hepatology and J Gastroenterol Hepatol, highlights his leadership in advancing knowledge about liver disease. Dr. Kim’s research and clinical expertise have earned him the trust and respect of colleagues in the medical community, solidifying his position as a leading expert in the field of internal medicine and hepatology.

🌍 Research Skills On Medicine

Dr. Do Young Kim’s research skills are highly regarded, particularly in the fields of hepatocellular carcinoma (HCC) and hepatitis C. He specializes in proteomics and microRNA, utilizing these molecular techniques to gain deeper insights into the pathophysiology of liver diseases. His time at the Fred Hutchinson Cancer Research Center honed his skills in advanced research methodologies, which he continues to apply in his work at Severance Hospital and Yonsei University College of Medicine. Dr. Kim’s research is both experimental and clinical, bridging the gap between laboratory findings and real-world medical applications. He is skilled in conducting large-scale studies, analyzing complex data, and collaborating with multidisciplinary teams to advance scientific understanding. His research has led to significant clinical improvements in the management of liver diseases, particularly in HCC treatment and early detection.

đź“– Publication Top Notes

  • Letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
    • Authors: Chon, Y.E., Kim, D.Y., Chon, H.J., Kim, D.Y.
    • Citation: Clinical and Molecular Hepatology, 2025, 31(1), pp. e98–e100
  • The Possible Impact of Zinc-Enriched Multivitamins on Treatment-NaĂŻve Recurrent Aphthous Stomatitis Patients
    • Authors: Seo, H.R., Chung, K.B., Kim, D.-Y.
    • Citation: Journal of Clinical Medicine, 2025, 14(1), 260
  • Survey on Alopecia Areata Patients’ Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study
    • Authors: Kim, J.E., Lee, S., Kang, H., Lee, Y.W., Kim, M.-B.
    • Citation: Annals of Dermatology, 2024, 36(6), pp. 376–383
  • Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study
    • Authors: Kim, K.-P., Kim, K.M., Ryoo, B.-Y., Kim, J.-A., Kim, K.-H.
    • Citation: Liver Cancer, 2024, 13(6), pp. 610–628
  • Detection of NUDT15 R139C Variants and Azathioprine Utilization in Patients with Dermatologic Conditions
    • Authors: Chung, K.B., Sung, H., Kim, D.-Y.
    • Citation: International Journal of Dermatology, 2024, 63(3), pp. e75–e77
  • Quantitative Analysis of Hair Luster in a Novel Ultraviolet-Irradiated Mouse Model
    • Authors: Chung, K.B., Lee, Y.I., Kim, Y.J., Kim, D.-Y., Lee, J.H.
    • Citation: International Journal of Molecular Sciences, 2024, 25(3), 1885
    • Citations: 1
  • Heterogeneity in Keloid Scars: Influence of Mechanical Stretching on Keloids Arising from Different Anatomical Sites
    • Authors: Lee, Y.I., Yang, Y., Ham, S., Kim, D.-Y., Lee, J.H.
    • Citation: Journal of Investigative Dermatology, 2024
  • The Efficacy of Treatment for Hepatocellular Carcinoma in Elderly Patients
    • Authors: Lee, H.A., Lee, S., Lee, H.L., Rhim, H., Kim, D.Y.
    • Citation: Journal of Liver Cancer, 2023, 23(2), pp. 362–376
    • Citations: 2
  • Predictive Biomarkers of Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Treatment
    • Authors: Chon, Y.E., Cheon, J., Kim, H., Chon, H.J., Kim, B.K.
    • Citation: Cancer Medicine, 2023, 12(3), pp. 2731–2738
    • Citations: 26
  • Activated TAZ Induces Liver Cancer in Collaboration with EGFR/HER2 Signaling Pathways
    • Authors: Moon, H., Park, H., Chae, M.J., Kim, D.Y., Ro, S.W.
    • Citation: BMC Cancer, 2022, 22(1), 423
    • Citations: 11